ViroMed Gene Therapy for Non-Healing Diabetic Foot Ulcers Starts Phase III Trial – Genetic Engineering & Biotechnology News
|
ViroMed Gene Therapy for Non-Healing Diabetic Foot Ulcers Starts Phase III Trial
Genetic Engineering & Biotechnology News The first patient has been dosed in a Phase III trial assessing ViroMed's VM202, the first pivotal study of a gene therapy indicated for patients with non-healing diabetic foot ulcers (NHU) and concomitant peripheral artery disease (PAD). The Phase 3 … |
